Lymphoma development in Sjogren's syndrome: Novel p53 mutations

Arthritis and Rheumatism

Volumn 42, Issue 7, 1999, Pages 1466-1472

  Tapinos, Nikolaos I ^a   Polihronis, Mary ^a   Moutsopoulos, Haralampos M ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOIMMUNITY; CARCINOGENESIS; CLONAL ANERGY; DNA DAMAGE; DNA DETERMINATION; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SJOEGREN SYNDROME; TUMOR SUPPRESSOR GENE; BIOPSY; DNA SEQUENCE; FEMALE; GENETICS; MIDDLE AGED; MUTATION; NONHODGKIN LYMPHOMA; PATHOLOGY; SALIVARY GLAND;

PROTEIN P21;

BIOPSY; FEMALE; GENES, P53; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MUTATION; ONCOGENE PROTEIN P21(RAS); SALIVARY GLANDS; SEQUENCE ANALYSIS, DNA; SJOGREN'S SYNDROME;

EID: 0033238091     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199907)42:7<1466::AID-ANR21>3.0.CO;2-L     Document Type: Article

References (37)

1. Hartwell JW, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
2. Hinds PW, Weinberg RA. Tumor suppressor genes. Curr Opin Genet Dev 1994;4:135-41.
3. Hollenstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutation in human cancers. Science 1991;253:49-53.
4. Maltzman W, Czyzk L. UV irradiation stimulates levels of p53 tumor antigen in non-transformed mouse cells. Mol Cell Biol 1984;4:1689-94.
5. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
6. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is a universal inhibitor of cyclin kinases. Nature 1993;366: 701-4.
7. Flores-Rozas H, Kelman Z, Dean FB, Pan Z, Harper JW, Elledge SJ, et al. Cdk-interacting protein-1 (Cip1, WAF1) directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc Natl Acad Sci U S A 1994;91:8655-9.
8. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-8.
9. Cip1 in muscle and other terminally differentiated cells. Science 1995;267:1024-7.
10. Firestein GS, Echeverri F, Yeo M, Zvaiffer NI, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997;94:10895-900.
11. Toda I, Wickham LA, Sullivan DA. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice. Clin Immunol Immunopathol 1998;86:59-71.
12. Polihronis M, Tapinos NI, Theocharis SE, Economou A, Kittas C, Moutsopoulos HM. Modes of epithelial cell death and repair in Sjögren's syndrome. Clin Exp Immunol 1998;114:485-90.
13. Schmid U, Helbron D, Lennert K. Development of malignant lymphoma in myoepithelial sialadenitis (Sjögren's syndrome). Virchows Arch 1982;395:11-43.
14. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
15. Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome: assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147-56.
16. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986;6:1379-85.
17. Farell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T. P53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 1991;10:2879-87.
18. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al. Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90:766-75.
19. Lindahl G, Hedfors E, Klareskog L, Forsum U. Epithelial HLA-DR expression and T lymphocyte subsets in salivary glands in Sjögren's syndrome. Clin Exp Immunol 1985;61:475-82.
20. Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol 1995;34:326-33.
21. Skopouli FN, Kousvelari EE, Mertz P, Jaffe ES, Fox PS, Moutsopoulos HM. C-myc mRNA expression in minor salivary glands of patients with Sjögren's syndrome. J Rheumatol 1992;19:693-9.
22. Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, Xanthou G, Paikos S, Polihronis M, et al. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. Arthritis Rheum 1999;42:229-39.
23. Kong L, Ogawa N, Nakabayashi T, Liu GT, D'Souza E, McGuff HS, et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997; 40:87-97.
24. CIP/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84.
25. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
26. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A which is inhibited by E1B. Genes Dev 1993;7:546-54.
27. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
28. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
29. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
30. Durdick I, Byard RW, Carnegie JA. A review of the proliferative capacity of major salivary glands and the relationship to current concepts of neoplasia in salivary glands. Oral Surg Oral Med Oral Pathol 1990;69:53-67.
31. Papadopoulos GK, Moutsopoulos HM. Slow viruses and the immune system in the pathogenesis of local tissue damage in Sjögren's syndrome. Ann Rheum Dis 1992;51:136-8.
32. Kohsaka H, Yammamoto K, Fujii H, Miura H, Miyasaka N, Nishioka K, et al. Fine epitope mapping of the human SSB/La protein: identification of a distinct autoepitope homologous to a viral gag polyprotein. J Clin Invest 1990;85:1566-74.
33. Green JE, Hinricks SH, Vogel J, Jay G. Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice. Nature 1989; 341:72-4.
34. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty T. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
35. Hatmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, de Vries EM, et al. P53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 1995;10:681-8.
36. Pisa EK, Pisa P, Kang HI, Fox RI. High frequency of t(14;18) translocations in salivary gland lymphomas from Sjögren's syndrome patients. J Exp Med 1991;174:1245-50.
37. Nigro MJ, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.